Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock
Company Appoints D. Keith Grossman to Board of Directors
April 8, 2026
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock
Company Appoints D. Keith Grossman to Board of Directors